An approximate 55 million people worldwide suffer from Dementia and Alzheimer's
Dementia and Alzheimer's are neurodegenerative dieseases that overtime plague the afflicted with a regressing or declining state that show symptoms of:
—devestating, not only the afflicted but family and loved ones as well. And with no cure or treatment available, it may seem bleak for those plagued with this disease, until now.
TauRx was founded by the visionary scientist Professor Claude wischik, and with the help of his team, have pioneered the research into tau protein. Spending over more than three decades, and dedicating that time into helping understand the implications of the tau protein, and how it affecs dementia has paved the way into this ground-breaking treatment.
TauRx's groundbreaking work hinges on the understanding of tau proteins and their role in neurodegenerative diseases. In a healthy brain, tau proteins help in the maintenance and stabilization of microtubules, which are vital structures inside neurons that help transport nutrients and other important substances.
However, in diseases like Alzheimer's, these proteins become defective and start to aggregate, forming 'tangles' that disrupt the normal functioning of neurons, leading eventually to their death. This buildup of tau proteins or plaque is one of the hallmarks of Alzheimer's and has been linked to the progression of the disease.
Phase III trials of LMTX® demonstrated its potential as a monotherapy for Alzheimer's disease. While the full cohort did not meet the primary endpoints, a significant subset of patients who took LMTX® as a monotherapy showed a marked slowing in disease progression.
The potential impact of TauRx's groundbreaking LMTX® discovery on Alzheimer's and other neurodegenerative diseases is immense. Alzheimer's disease alone affects more than 50 million people worldwide, a number projected to triple by 2050. The current treatments only manage the symptoms without addressing the disease's progression, leaving a significant unmet need for disease-modifying therapies.
LMTX®, with its novel mechanism of action targeting Tau pathology, could revolutionize the treatment paradigm. Preclinical and clinical trial data suggest that it not only halts disease progression but may even reverse some effects, something no other Alzheimer's therapy has achieved so far.
Firstly, the global Alzheimer's disease therapeutics market is expected to reach over $14.8 billion by 2027, and that's without considering other Tau-related neurodegenerative diseases. With a potentially disease-modifying therapy like LMTX®, TauRx is poised to capture a significant market share.
Secondly, TauRx is a leader in Tau pathology research, one of the most promising new approaches in neurodegenerative disease treatment. The company's robust patent portfolio, with patents covering LMTX® and its use, provides a significant competitive advantage.
Thirdly, TauRx has a solid clinical development program. The positive data from its clinical trials of LMTX® demonstrate the drug's potential and de-risk the investment to a certain extent.
Lastly, investing in TauRx means contributing to a cause that can make a real difference in millions of lives globally—application approval pending for Europe, US and Dubai. Currently expected cost prices are 50% less than any existing medical application or treatment out there. With side effects only limited to a blue discoloration of urine.
To commemorate the recent announcment of our IXS Launchpad. The IX Swap team has been able to gather a number of shares of TauRx through an angel investor.
What does this mean for you?
As a retail investor getting into these high-profile private asset classes and companies are well, rather expensive. Through blockchain technology, and our launchpad, we are able to fractionalize these shares. Ultimately allowing you, our everyday investor the opportunity to take part in the leading medical treatment for Dementia and Alzheimer's, for only a minimum spend of $1.
Follow our guide here
Click on this link here
Registration's running from July 24 - July 31, so don't miss out!
Got questions and concerns? Joins us on Telegram